Haleon plc (HLN) on Decifer

Decifer ranks HLN number 275 of 277 tracked names on durable business quality.

Why it ranks here

• Its returns on invested money are modest, around 7% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is expected to grow about 4% a year, profits grew 12% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Steady high margins are reassuring but returns around 7%, revenue growing only about 4% a year, and no worldview role leave little to move it.

The current read

The evidence on HLN lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Haleon plc operates in drug manufacturers - specialty & generic. That places it inside the Healthcare, Biotech & Devices story.

Read the full HLN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.